23 May, 2017
Chevron Corporation manages its investments in subsidiaries and affiliates, and provides administrative, financial, management and technology support to the United States and worldwide subsidiaries that engage in integrated energy and chemicals operations. The company has market cap of $35.10 billion. It has a 120.85 P/E ratio.
Aristotle Fund L.P. holds 11.49% of its portfolio in McKesson Corporation for 105,000 shares. Adams Natural Resources Fund Inc. owns 575,600 shares or 10.09% of their United States portfolio. Moreover, Healthinvest Partners Ab has 7.38% invested in the company for 57,000 shares. Tpg, a Alabama-based fund reported 68,181 shares.
Ratings analysis reveals 69% of Chevron Corporation's analysts are positive. Jefferies has "Hold" rating and GBX 1099 target. The lowest target is $65 while the high is $147. The stock's average target of $191.53 is 25.17% above today's ($153.01) share price. CVX was included in 58 notes of analysts from August 4, 2015. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company's stock. The firm has "Hold" rating given on Thursday, June 30 by Jefferies. The rating was downgraded by Robert W. Baird to "Neutral" on Friday, October 28. The rating was maintained by AlphaValue on Wednesday, November 11 with "Buy". The firm earned "Outperform" rating on Thursday, December 15 by Macquarie Research. British American Tobacco PLC (ADR) (NYSEMKT:BTI) has risen 17.78% since May 22, 2016 and is uptrending. It has by 0.00% the S&P500. The stock's market cap is GBX 209.17 million. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. It has a 33.96 P/E ratio. The Company's segments include Branded, Injectables, Generics and Others.
Dechra Pharmaceuticals plc (LON:DPH) has earned an average rating of "Buy" from the eight brokerages that are covering the stock. Therefore 80% are positive. Finally, Stifel Nicolaus restated a buy rating and set a GBX 150 ($1.94) target price on shares of Circassia Pharmaceuticals PLC in a research report on Tuesday, April 4th. GBX 1479.44's average target is -19.15% below currents GBX 1829.85 stock price. N+1 Singer reaffirmed a "buy" rating and issued a GBX 1,600 ($20.65) price target on shares of Dechra Pharmaceuticals plc in a research note on Monday, February 27th. The firm earned "Buy" rating on Thursday, March 10 by AlphaValue. The rating was maintained by JP Morgan with "Overweight" on Tuesday, January 17. The rating was maintained by HSBC with "Reduce" on Friday, May 5. The company was maintained on Wednesday, August 24 by Numis Securities. The stock has "Overweight" rating by JP Morgan on Tuesday, November 10. Jefferies maintained the stock with "Buy" rating in Tuesday, July 26 report.
Hikma Pharmaceuticals Plc (LON:HIK) traded down 3.5483% on Friday, hitting GBX 1674.4016. JP Morgan maintained Hikma Pharmaceuticals Plc (LON:HIK) on Wednesday, January 4 with "Overweight" rating.
About 368,128 shares traded.
TRADEMARK VIOLATION WARNING: "Hikma Pharmaceuticals Plc (HIK) Cut to "Underperform" at Jefferies Group LLC" was originally published by Stock Observer and is the property of of Stock Observer.
